Navigation Links
Novavax Announces Early Retirement of $17 Million of Convertible Debt
Date:4/29/2009

nt vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statement

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
2. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
3. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
4. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
5. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
6. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
7. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
8. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
9. Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
10. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
11. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... ... July 03, 2015 , ... The Alexander Group, ... professional service industries alike-- typically known for its consummate professionalism-- embarks each year ... cause and break from their day jobs. , "Our motto has always been ...
(Date:7/3/2015)... July 3, 2015 ... Open Innovation in Science", som finner sted ... sendes på nett, på  http://www.openinnovationinscience.at , og ... De to største utfordringene innen ... undersøke nye forskningsspørsmål og kompleksiteten av nåværende ...
(Date:7/2/2015)... ... 03, 2015 , ... Cuvettes have been used in countless labs for decades. In the ... they needed. As expected, this was a daunting and tiring process looking at endless ... were not able to navigate the complex catalog structure. , Now thanks to FireflySci, scientists ...
(Date:7/2/2015)... Scotland , July 2, 2015 ... Bio-tech procurement company Amici Procurement has chosen ... to help it move to Office 365. ... provides small to medium-sized companies in the bio-tech ... all aspects of the purchasing cycle to help them ...
Breaking Biology Technology:The Alexander Group Declares Their Independence with a Bit of Levity 2Lansering av verdens første Open Innovation-program for utdanning av forskere 2Lansering av verdens første Open Innovation-program for utdanning av forskere 3New Cuvette E-Commerce Website Launched by FireflySci 2Biotech Procurement Company Moves to Office 365 with iomart 2
... MGCD0103,s Orphan Drug, Designation for the Treatment of ... BOULDER, Colo. and MONTREAL, Sept. 24 ,Pharmion Corporation ... MYG) today,announced that the European Medicines Agency (EMEA) ... deacetylase (HDAC),inhibitor, as an Orphan Medicinal Product for ...
... September 24 Nitec Pharma AG today,announced that ... accepted the,Investigational New Drug (IND) application submitted by ... Following the positive results of a European ... Rheumatoid Arthritis), Nitec,submitted a dossier for marketing authorization ...
... of XYOTAX(R) for Women with ... Advanced Non-Small Cell Lung Cancer, SEATTLE, Sept. 24 Cell ... a confirmatory phase,III clinical trial of combination chemotherapy for women with ... women,today. The trial, known as PGT307, will focus exclusively on women ...
Cached Biology Technology:Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma 2Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma 3Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma 4Nitec's IND Application for Clinical Development With Lodotra Accepted by the FDA 2Nitec's IND Application for Clinical Development With Lodotra Accepted by the FDA 3Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer 2Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer 3Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer 4Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer 5
(Date:6/23/2015)... June 23, 2015  Crossmatch™, a leading ... today announced enhanced functionality of its DigitalPersona ... The enhancements build on the native flexibility ... Altus platform and provide expanded mobile credential ... In today,s environment of increasing cyber-attacks and ...
(Date:6/17/2015)... SAN JOSE, Calif. , June 17, 2015 ... leader in human interface solutions, today announced that ... has adopted the Synaptics ® ClearPad ® ... family of display driver integrated circuits (DDICs) for ... Note Pro. By leveraging ClearPad for full in-cell ...
(Date:6/16/2015)... Fingerprint Cards (FPC) raises the revenue ... amount to at least 340 MSEK to that it will ... in market growth and orders received the revenue guidance for ... for 2015 will exceed 1,500 MSEK to an updated guidance ... Due to receipt of orders of touch fingerprint ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3
... LANSING, Mich. A Michigan State University researcher is ... food to be harmful. Norman Hord,s research suggests ... the use of nitrogen-based fertilizers and excessive nitrates in ... plants -- may actually provide health benefits. Nitrate ...
... DURHAM, N.C. The lowly appendix, long-regarded as a useless ... at Duke University Medical Center proposed that it actually serves ... haven where good bacteria could hang out until they were ... diarrhea, for example. Now, some of those ...
... heat almost as well as adults, a finding that runs ... should be more vulnerable in extreme cold. The study, by ... be published in the forthcoming issue of Physiological and ... any animal, but it is generally assumed to be tougher ...
Cached Biology News:Research supports calls to study health benefits of nitrate, nitrite 2Evolution of the appendix: A biological 'remnant' no more 2Evolution of the appendix: A biological 'remnant' no more 3Study: Young Arctic muskoxen better at keeping warm than scientists thought 2
EZ-DeWax is a one-step solution that simultanously removes paraffin from and rehydrates formalin-fixed, paraffin embedded tissue...
... Gene Cycler unit is an inexpensive personal or ... the PCR process. Lightweight, with a small footprint, ... anywhere, including the researcher's desk. , The Gene ... who do not have access to a large ...
... Red fluorescent RNA stain is used to ... or glyoxal) agarose gels and does not ... a 302 nm transilluminator, the stain emits ... on Polaroid film or with a CCD ...
From the company that first brought you the chromatin immunoprecipitation (ChIP) kit, a new and improved kit, EZ-ChIP, is now available to make your experiments easier, quicker, and most importantly,...
Biology Products: